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Purpose: To report the clinical, ophthalmic, and genetic characteristics for lattice corneal dystrophy type I (LCDI) in a
Chilean family.
Methods: Six affected family members were examined clinically including visual acuity, color cornea photography,
applanation tonography, and fundoscopy. Genomic DNA was extracted from peripheral leukocytes from six affected and
three unaffected members of a family with lattice corneal dystrophy type I. Exon 4 of the transforming growth factor-
induced gene (TGFBI) was screened for the most frequent mutation, R124C, in the proband by sequencing. We also
designed a rapid polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method to analyze
the same mutation, amplifying exon 4 and digesting with PstI restriction enzyme. Using this strategy, we analyzed the
mutation in six affected and three healthy family members.
Results: Three generations of family members were positively diagnosed with lattice corneal dystrophy. Six participants
demonstrated LCD1 in both eyes, most of whom were symmetric. Age at onset of symptoms was variable (3–42 years
old). Moreover, in this family, the age of onset of the disease decreased in succeeding generations, which could be
interpreted as anticipation. Visual acuity varied from 1.0 to 0.13. Two patients, ages 69 and 44 years old, demonstrated a
degree of severity “Bad” according to best-corrected vision and corneal commitment. The exon 4 sequence of TGFBI of
the proband exhibits the heterozygous single-nucleotide mutation, C417T, leading to amino acid substitution (R124C) in
the encoded TGF–induced protein. Using PCR-RFLP, we confirmed the heterozygous mutation in six affected family
members and excluded it in three healthy members.
Conclusions: The R124C mutation in TGFBI cosegregated with LCD type I in the investigated family. This is the first
report of a molecular analysis of LCD type I in Chilean patients. The early onset affected persons in the fourth generation
raises the possibility of anticipation.
The  corneal  dystrophies  are  a  group  of  genetically
determined diseases usually characterized by loss of corneal
transparency,  which  may  be  caused  by  a  progressive
accumulation of abnormal material within the cornea. Lattice
corneal  dystrophy  (LCD)  is  a  distinct  clinical  entity
characterized by the accumulation of amyloid throughout the
middle and anterior stroma [1].
Lattice  corneal  dystrophy  type  I  (LCD1,  OMIM
122200), also known as Biber-Haab-Dimmer dystrophy, is
inherited as an autosomal dominant trait with variable clinical
expression and a high degree of penetration [2]. Generally, the
first clinical symptoms become evident in the first or second
decade with the appearance of white-grayish opacities, which
involve the superficial stromal layer of the cornea. Thereafter,
the  lesions  tend  to  become  larger,  aggregate,  and  extend
deeper and toward the periphery.
In 1994, a gene for several corneal dystrophies [3] and the
transforming  growth  factor-induced  gene  (TGFBI,  also
known as BIGH3) [4] were mapped to human chromosome 5
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(5q31). During the same year, it was also discovered that the
protein product of the TGFBI gene is expressed in the cornea
[5]. Three years later, Munier et al. [6] reported that these
disorders are caused by mutations in TGFBI. Mutations in the
same gene also cause granular corneal dystrophies (GCD;
reviewed by Kannabiran and Klintworth [7]). TGFBI encodes
for a 68 kDa extracellular matrix protein [4].
So far, few mutations have been described in this gene as
causative of LCD type I. The mutation list includes R124C,
V505D, L518P, V539D, A546D, P551Q, L569R, H572R, and
V625D [7-9]. The mutation C>T at the nucleotide position
417 at codon 124 (R124C) in exon 4 is the most frequent
throughout the world [6,10-21].
Considering that there are no genetic studies on lattice
corneal dystrophy in our country, we determined the clinical,
ophthalmic, and genetic characteristics in a Chilean family
having this disease. Our results suggest anticipation in the
disease. We report for the first time the presence of the TGFBI
mutation segregating with lattice corneal dystrophy type I in
Chilean patients. The molecular basis of anticipation in LCDI,
which is not mediated by trinucleotide repeat expansions in
the BIGH3, remains elusive.
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Patients:  The  present  study  was  approved  by  the  Ethics
Committee of the Clinical Hospital University of Chile and
adhered  to  the  tenets  of  the  Declaration  of  Helsinki.  The
pedigree of the four-generation family was delineated (Figure
1). After obtaining informed consent, nine members from
three consecutive generations of a Chilean family with lattice
corneal  dystrophy  were  enrolled,  six  affected  and  three
unaffected. The proband was initially examined because of
ocular pain and redness. The LCD type I diagnosis was made
on the basis of clinical examination. The nine members of the
family, affected and not affected, were examined over two
years. The family history suggests Spanish origin.
Clinical  evaluations:  An  extensive  clinical  history  of
participating  members  of  the  family  was  developed  and
particular attention was paid to the age of onset, initial signs
and symptoms, and corneal structure. Clinical examination
included best corrected visual acuity according to the best line
of  Snellen  acuity,  slit  lamp  biomicroscopy,  color  cornea
photography,  applanation  tonography,  and  dilated  fundus
examination.  Autorefractometry  measurement  and
keratometry  were  performed  (Topcon  RM-A7000,  Tokyo,
Japan). Stereopsis was quantitatively assessed with the Titmus
Fly Stereo Test (Stereo Optical Co., Inc., Chicago, IL) [22].
The lesions were considered to be synchronic if the patients
perceived  the  first  symptoms  in  both  eyes  with  a  time
difference of less than a month. All individuals with corneal
commitment  were  considered  clinically  affected.  Patients
were  classified  in  degree  of  severity  according  to  best-
corrected vision (Table 1) and the number of lesions and
corneal  commitment.  The  corneal  phenotype  of  all  index
patients was assessed by slit lamp biomicroscopy examination
and reviewed by an investigator ignorant of the genetic status.
Although the patients, II-1, III-2 and IV-2, were not examined
Figure 1. Pedigree showing a four-generation family affected by
lattice corneal dystrophy type I. Autosomal dominant transmission
of the disease is evident. Circles represent females, squares represent
males  and  a  slash  mark  through  the  square  or  circle  indicates
deceased. The arrow indicates the proband, and the filled symbols
indicate  affected  individuals.  Asterisks  indicate  members  of  the
family who underwent clinical examination and molecular analyses.
in  this  study,  their  age  of  onset  were  obtained  from  an
interview of patient II-1.
Molecular analysis: Blood samples were colleted in tubes
containing  EDTA  and  total  DNA  was  prepared  from
peripheral blood lymphocytes [23]. Exon 4 of the proband was
amplified  using  previously  described  primers  [24].  The
resulting  polymerase  chain  reaction  (PCR)  product  was
purified  using  the  Wizard®  Gel  purification  kit  (Promega
Corporation, Madison, WI) and sequenced using Big DyeTM
sequencing reagents (Applied Biosystems, Foster city, CA),
and  automated  sequencing  was  performed  by  capillary
electrophoresis  on  an  ABI3700  (Applied  Biosystems).  To
analyze the same mutation in the nine family members, we
designed a new simple and rapid detection method based on
polymerase  chain  reaction-restriction  fragment  length
polymorphism analysis (PCR-RFLP). To carry out the PCR-
RFLP analyses, genomic DNA from nine family members
was amplified by PCR using the primers BIGH3 F1: 5′-CTT
TCC CAC ATG CCT CCT CGT-3′ (forward) and BIGH3
Rmut:  5′-TCT  CAG  GCC  TCA  GCT  TCT  CCC  TGC-3′
(reverse). The “T” nucleotide at position 21 in the sequence
of the reverse primer was replaced for a “C” to generate the
PstI restriction site in the mutated allele. The 221 products
were digested using the PstI restriction enzyme for 3 h at
37 °C. Fragments were resolved by electrophoresis in a 4%
Nusieve agarose (3:1) gel, stained with ethidium bromide, and
visualized under ultraviolet light. After digestion, the “T”
allele consisted of three fragments of 21, 76, and 124 base
pairs (bp), and the “C” allele consisted of two fragments of 97
and 124 bp.
RESULTS
Clinical  findings:  The  four-generation  lattice  corneal
dystrophy type I family studied consisted of nine affected and
nine unaffected individuals (Figure 1). Eight relatives of the
proband were examined clinically. Five of them were affected
by LCD type I (two males and three females) and three were
not affected (two males and one female), as shown in the
pedigree (Figure 1). The phenotypic features of affected and
unaffected family members are summarized in Table 1. The
age of onset of patients II-1, III-2, and IV-2 were obtained
from an interview of patient II-1, although they were not
clinically analyzed in this study. The proband was an eight-
year-old boy (IV-5). The presence of LCD type I in three
continuous  generations  indicates  an  autosomal  dominant
transmission.  All  patients  clinically  studied  reported  the
beginning of lesions in a synchronic way in both eyes except
for patient II-2 who noticed the lesion in the second eye one
year after the lesion in the first eye. Visual sharpness ranged
from 1.0 to 0.13; the worst were in the older generations. All
patients had different degrees of astigmatism, with intraocular
pressure (IOP) within the normal range (IOP<21) and had
normal stereopsis.
Molecular Vision 2008; 14:829-835 <http://www.molvis.org/molvis/v14/a98> © 2008 Molecular Vision
830T
A
B
L
E
 
1
.
 
C
L
I
N
I
C
A
L
 
F
E
A
T
U
R
E
S
 
I
N
 
T
H
E
 
A
F
F
E
C
T
E
D
 
A
N
D
 
U
N
A
F
F
E
C
T
E
D
 
F
A
M
I
L
Y
 
M
E
M
B
E
R
S
.
B
e
s
t
-
c
o
r
r
e
c
t
e
d
v
i
s
i
o
n
C
a
s
e
A
g
e
G
e
n
d
e
r
S
t
a
t
u
s
A
g
e
 
o
f
 
o
n
s
e
t
O
D
O
S
C
o
r
n
e
a
l
 
l
e
s
i
o
n
s
S
y
n
c
h
r
o
n
i
c
S
y
m
m
e
t
r
y
D
e
g
r
e
e
*
D
e
g
r
e
e
*
*
I
I
-
1
7
3
F
A
f
f
e
c
t
e
d
3
7
Y
e
s
#
I
I
-
3
6
9
M
A
f
f
e
c
t
e
d
4
2
0
.
1
3
0
.
1
3
Y
e
s
Y
e
s
N
o
B
a
d
4
I
I
-
4
6
8
F
N
o
t
 
a
f
f
e
c
t
e
d
-
1
1
I
I
I
-
2
5
5
M
A
f
f
e
c
t
e
d
1
7
Y
e
s
#
#
I
I
I
-
4
4
2
M
N
o
t
 
a
f
f
e
c
t
e
d
-
1
1
I
I
I
-
5
4
4
F
A
f
f
e
c
t
e
d
3
0
0
.
2
8
0
.
1
3
Y
e
s
N
o
Y
e
s
B
a
d
4
I
I
I
-
6
4
0
F
A
f
f
e
c
t
e
d
2
8
0
.
5
0
.
4
Y
e
s
Y
e
s
Y
e
s
I
n
t
e
r
m
e
d
i
a
t
e
3
I
I
I
-
7
4
3
M
N
o
t
 
a
f
f
e
c
t
e
d
-
1
1
I
V
-
2
1
6
F
A
f
f
e
c
t
e
d
5
I
V
-
3
1
5
M
A
f
f
e
c
t
e
d
3
1
1
Y
e
s
Y
e
s
Y
e
s
V
e
r
y
 
g
o
o
d
1
I
V
-
4
1
5
F
A
f
f
e
c
t
e
d
4
1
1
Y
e
s
Y
e
s
Y
e
s
V
e
r
y
 
g
o
o
d
1
I
V
-
5
8
M
A
f
f
e
c
t
e
d
4
0
.
5
0
.
6
7
Y
e
s
Y
e
s
N
o
G
o
o
d
2
T
h
e
 
p
h
e
n
o
t
y
p
i
c
 
f
e
a
t
u
r
e
s
 
o
f
 
n
i
n
e
 
p
a
t
i
e
n
t
s
 
f
r
o
m
 
t
h
e
 
f
a
m
i
l
y
 
a
f
f
e
c
t
e
d
 
b
y
 
l
a
t
t
i
c
e
 
t
y
p
e
 
I
 
a
r
e
 
s
h
o
w
n
.
 
T
h
e
 
a
g
e
 
o
f
 
o
n
s
e
t
 
o
f
 
p
a
t
i
e
n
t
s
 
I
I
-
1
,
 
I
I
I
-
2
,
 
a
n
d
 
I
V
-
2
 
w
e
r
e
 
o
b
t
a
i
n
e
d
 
f
r
o
m
a
n
 
i
n
t
e
r
v
i
e
w
 
o
f
 
p
a
t
i
e
n
t
 
I
I
-
1
.
 
C
o
r
n
e
a
l
 
p
h
e
n
o
t
y
p
e
s
 
w
e
r
e
 
a
s
s
e
s
s
e
d
 
b
y
 
s
l
i
t
 
l
a
m
p
 
e
x
a
m
i
n
a
t
i
o
n
.
 
T
h
e
 
l
e
s
i
o
n
s
 
w
e
r
e
 
c
o
n
s
i
d
e
r
e
d
 
t
o
 
b
e
 
s
y
n
c
h
r
o
n
i
c
 
i
f
 
t
h
e
 
p
a
t
i
e
n
t
s
 
p
e
r
c
e
i
v
e
d
 
t
h
e
f
i
r
s
t
 
s
y
m
p
t
o
m
s
 
a
t
 
m
o
s
t
 
a
 
m
o
n
t
h
 
a
p
a
r
t
 
i
n
 
e
a
c
h
 
e
y
e
.
 
T
h
e
 
d
e
g
r
e
e
 
o
f
 
s
e
v
e
r
i
t
y
 
w
a
s
 
c
l
a
s
s
i
f
i
e
d
 
a
c
c
o
r
d
i
n
g
 
t
o
 
b
e
s
t
-
c
o
r
r
e
c
t
e
d
 
v
i
s
i
o
n
 
o
r
 
c
o
r
n
e
a
l
 
c
o
m
m
i
t
m
e
n
t
.
 
T
h
e
 
d
e
g
r
e
e
 
o
f
s
e
v
e
r
i
t
y
 
a
c
c
o
r
d
i
n
g
 
t
o
 
b
e
s
t
-
c
o
r
r
e
c
t
e
d
 
v
i
s
i
o
n
 
w
a
s
 
c
l
a
s
s
i
f
i
e
d
 
a
s
 
v
e
r
y
 
g
o
o
d
 
(
>
0
.
6
)
,
 
g
o
o
d
 
(
<
0
.
6
 
a
n
d
 
>
0
.
4
)
,
 
i
n
t
e
r
m
e
d
i
a
t
e
 
(
<
0
.
4
 
a
n
d
 
>
0
.
3
3
)
,
 
a
n
d
 
b
a
d
 
(
<
0
.
3
3
)
.
 
T
h
e
 
d
e
g
r
e
e
 
o
f
s
e
v
e
r
i
t
y
 
a
c
c
o
r
d
i
n
g
 
t
o
 
c
o
r
n
e
a
l
 
c
o
m
m
i
t
m
e
n
t
 
w
a
s
 
c
l
a
s
s
i
f
i
e
d
 
a
s
 
f
o
l
l
o
w
s
 
1
)
 
w
i
t
h
o
u
t
 
l
e
s
i
o
n
s
,
 
2
)
 
s
u
b
e
p
i
t
h
e
l
i
a
l
,
 
w
h
i
t
e
-
g
r
a
y
i
s
h
 
o
p
a
c
i
t
i
e
s
,
 
3
)
 
r
e
f
r
a
c
t
i
l
e
 
l
a
t
t
i
c
e
 
l
i
n
e
s
,
 
a
n
d
 
4
)
c
o
r
n
e
a
l
 
e
d
e
m
a
.
 
T
h
e
 
f
o
l
l
o
w
i
n
g
 
a
b
b
r
e
v
i
a
t
i
o
n
s
 
w
e
r
e
 
u
s
e
d
 
r
i
g
h
t
 
e
y
e
 
(
O
D
)
 
a
n
d
 
l
e
f
t
 
e
y
e
 
(
O
S
)
.
 
I
n
 
t
h
e
 
t
a
b
l
e
,
 
t
h
e
 
a
s
t
e
r
i
s
k
 
i
n
d
i
c
a
t
e
s
 
t
h
e
 
d
e
g
r
e
e
 
a
c
c
o
r
d
i
n
g
 
t
o
 
b
e
s
t
-
c
o
r
r
e
c
t
e
d
v
i
s
i
o
n
;
 
t
h
e
 
d
o
u
b
l
e
 
a
s
t
e
r
i
s
k
 
i
n
d
i
c
a
t
e
s
 
t
h
e
 
d
e
g
r
e
e
 
a
c
c
o
r
d
i
n
g
 
t
o
 
c
o
r
n
e
a
l
 
c
o
m
m
i
t
m
e
n
t
;
 
t
h
e
 
s
h
a
r
p
 
(
h
a
s
h
 
m
a
r
k
)
 
i
n
d
i
c
a
t
e
s
 
a
 
c
o
r
n
e
a
l
 
t
r
a
n
s
p
l
a
n
t
 
a
t
 
4
3
 
y
e
a
r
s
 
o
f
 
a
g
e
;
 
a
n
d
 
t
h
e
d
o
u
b
l
e
 
s
h
a
r
p
 
i
n
d
i
c
a
t
e
s
 
a
 
c
o
r
n
e
a
l
 
t
r
a
n
s
p
l
a
n
t
 
a
t
 
5
5
 
y
e
a
r
s
 
o
f
 
a
g
e
.
Molecular Vision 2008; 14:829-835 <http://www.molvis.org/molvis/v14/a98> © 2008 Molecular Vision
831Case II-3—The proband’s grandfather, at 69 years of
age, was examined and diagnosed with LCD. His symptoms
initiated with sensitivity to sunlight, episodes of ocular pain,
and redness at 42 years of age. Slit-lamp examination revealed
irregularity of the epithelial surface with subepithelial and
anterior stromal scarring resulting in diffuse clouding of the
central cornea (Figure 2A,B). Asymmetric commitment and
vascularization of the cornea was observed. He was classified
in maximal severity according to best-corrected vision (0.13
for  both  eyes)  and  corneal  commitment.  Typical,  fine
branching lattice lines could be seen in the peripheral anterior
stroma, which was outside the area of central opacification.
Central corneal sensation was significantly decreased, and the
patient had a history of recurrent corneal erosions in the fourth
and fifth decades of life.
Figure 2. Corneal phenotype analyzed by slit lamp examination. Slit
lamp  photographs  of  patient  II-3  at  69  years  of  age  show  an
irregularity of the epithelial surface with subepithelial and anterior
stromal scarring, resulting in diffuse clouding of the central cornea
(A and B; OD and OS, respectively). The image of Patient III-5 at
42 years of age shows a network of linear opacities associated with
other  smaller  opaque  spots  and  refractile  lattice  lines  (C).  The
photographs of case III-6 at 40 years of age show the appearance of
corneal grafts (D and E). The left cornea contains opacifications from
presumed recurrent disease (D). Fine branching lattice lines may be
seen in the peripheral anterior stroma (E). The image of patient IV-5
at eight years of age shows the presence of large, ropy lattice lines
in  the  anterior  stroma.  A  clear  area  is  preserved  around  the
corneoscleral limbus (F).
Case III-5—The symptoms of the proband’s aunt began
with episodes of acute ocular pain, redness, and photophobia
at  30  years  of  age.  The  frequency  and  severity  of  these
episodes increased coincident with a gradual deterioration of
vision in both eyes. At 42 years of age, she was classified in
maximal severity according to best-corrected vision (0.28 in
the right eye [OD] and 0.13 in the left eye [OS]) and corneal
commitment.  Slit-lamp  examination  revealed  an  irregular
epithelial  surface  with  subepithelial  and  anterior  stromal
scarring, resulting in diffuse clouding of the central cornea.
She showed a network of linear opacities associated with other
smaller opaque spots and refractive lattice lines (Figure 2C).
No  vascularization  of  the  cornea  was  observed.  Central
corneal sensation was decreased.
Case III-6—The proband’s mother, at 40 years of age,
initially  presented  a  mild  subepithelial  scarring  and
opacification, which gradually progressed to include elevated
subepithelial  opacities,  fine  lattice  lines,  diffuse  “ground
glass” haze in the anterior stroma, and corneal grafts (Figure
2D,E). Best-corrected vision was 0.5 OD and 0.4 OS. The left
cornea  contained  opacifications  from  presumed  recurrent
disease.  Fine  branching  lattice  lines  could  be  seen  in  the
peripheral anterior stroma.
Cases IV-3 and IV-4—Although patients IV-3 and IV-4
did not have lesions at time of the exams, they had a history
of recurrent corneal erosions in both eyes since the ages of
three and four, respectively.
Case  IV-5—The  proband  had  a  history  of  recurrent
corneal erosions in both eyes, which began when he was four
years old. Slit lamp examination showed the presence of large,
typical fine branching lattice lines in the anterior stroma in
OD  (Figure  2F).  A  clear  area  was  preserved  around  the
corneal-scleral limbus. Best-corrected vision was 0.5 in the
right eye (OD) and 0.67 in the left eye (OS).
The average age at onset for affected family members was
18.9±15.7 years old (3–42 years old; Table 1). However, the
age of the beginning of symptoms has been progressively
younger in succeeding generations. Generation II includes
two individuals (II-1 and II-3) with the age of onset at 37 and
42  years  old,  respectively;  generation  III  includes  three
individuals (III-2, III-5, and III-6) with the age of onset at 17,
28, and 30 years old, respectively; and generation IV includes
four individuals (IV-2, IV-3, IV-4, and IV-5) with the age of
onset at 5, 3, 4, and 4 years, respectively.
Molecular genetic analyses: Exon 4 of TGFB1 of the proband
was  analyzed  by  sequencing  (Figure  3).  The  sequence
revealed  a  heterozygous  missense  mutation,  R124C
(417C>T).  To  discriminate  between  normal  and  mutated
alleles,  we  developed  a  new  PCR-RFLP  method.  The
mutation was analyzed in six affected (including the proband)
and  three  healthy  family  members,  revealing  an  identical
heterozygous  change  in  all  affected.  As  expected,  the
mutation was absent in the unaffected individuals (Figure 4).
Molecular Vision 2008; 14:829-835 <http://www.molvis.org/molvis/v14/a98> © 2008 Molecular Vision
832DISCUSSION
All  affected  family  members  showed  phenotypic
characteristics  corresponding  to  LCDI.  Within  the  family
group, the patients showed a variable commitment that might
be explained not only with the course of the variant disease
but also with the amount of stromal damage over the years,
which apparently increased with age.
We report a case with a heterozygous mutation detected
by sequencing in exon 4 of TGFBI. This alteration has been
reported previously in several ethnic groups [6,11-21]. The
molecular analysis by the PCR-RFLP method developed here
offers an easy, rapid, and accurate diagnosis of patients with
R124C.
The genealogical information for the family allows us to
trace  the  mutation  only  as  far  as  the  proband’s  maternal
grandfather who seems to be of Spanish origin. There is no
information indicating that the great grandparents had any
ophthalmic disorder, which suggests this is a new mutation.
Figure  3.  Detection  of  the  pathogenic  mutation  (R124C)  in  the
proband. The DNA sequence around codon 124 of the TGFBI gene
is presented. The sequence in the proband shows a heterozygous,
single-base C to T transition at nucleotide 417 (R124C) in the sense
strand. The codon numbers are indicated at the top of the figure.
Figure 4. Analysis of R124C mutation by polymerase chain reaction-
restriction fragment length polymorphism. All affected individuals
carry the same mutation in exon 4 of the TGFBI gene. Exon 4 was
amplified from each family member and digested with PstI. The
products were analyzed by a 4% agarose gel electrophoresis along
with a standard marker (MW) as indicated.
We  observed  a  decrease  in  the  age  of  onset  in  three
succeeding  generations  in  the  family  of  the  proband.
Analyzing previous reports of LCD1 families, we found one
case describing the same point mutations in a family with
decreasing age of diagnosis in successive generations similar
to ours [25], although they do not document the age of onset.
This could be similarly interpreted as genetic anticipation of
the disease. Anticipation has been frequently described for
diseases caused by the expansion of unstable triplet repeats,
which is not the case with LCD1.
Anticipation has been also described for point mutations,
insertions, and deletions of a small group of genes including
TCOF1, located in 5q32 and mutated in Treacher Collins
syndrome (TCS; OMIM 154500) [26]; EBP, a gene located
in Xp11.22-p11.23 and mutated in X-chromosomal dominant
chondrodysplasia syndrome (CHH, OMIM 302960) [27]; the
transthyretin gene (TTR), located in 18q12.1 and mutated in
familial  amyloid  polyneuropathy  (FAP,  OMIM:176300])
[28]; and copper–zinc superoxide dismutase 1 (SOD1), a gene
located  in  21q22.1  and  mutated  in  amyotrophic  lateral
sclerosis (ALS, OMIM 105400). In some of these diseases, a
genetic explanation of anticipation has been suggested. For
example,  in  the  chondrodysplasia  syndrome,  somatic
mosaicism and differences in X chromosome inactivation can
explain  the  phenomenon  of  anticipation  and  in  amyloid
polyneuropathy, the differences in the age of disease onset
might be explained by genetic interactions among multiple
loci.
In our case, genetic anticipation might be explained in at
least  three  ways.  One  way  is  the  fact  that  a  previous
ophthalmic history of the parents and grandparents probably
prompted the family to look earlier for medical examination.
It  is  possible  that  several  mild  cases  of  the  syndrome,
especially when the affected person does not feel impaired,
will go undiagnosed until the occurrence of a more severely
affected  sibling  or  offspring.  Another  explanation  of
anticipation may be the result of the loss of a protective allele
or another interacting gene from the affected parent. Thus the
protective allele or interacting gene could ameliorate the effect
of  the  mutated  allele  in  the  affected  parent.  Since  such
protective allele or protective gene could be absent in the
offspring, it can not exhibit any protective effect in these
subjects.  The  final  possible  way  may  be  the  gain  of  a
susceptibility allele from the non-affected parent, which could
worsen the effect of the mutated allele. If we consider that
individuals III-4 and III-7 are not related, the probability of
gaining a susceptibility allele simultaneously by individuals
IV-3, IV-4, and IV-5 is low.
In  conclusion,  since  the  mutation  at  the  hot  spot
nucleotide 417 can be easily, rapidly, and cost-effectively
evaluated by PCR sequencing or by PCR-RFLP, identification
of this mutation will allow Chilean patients to benefit from a
timely  and  accurate  molecular  diagnosis  of  LCD  type  I.
Molecular Vision 2008; 14:829-835 <http://www.molvis.org/molvis/v14/a98> © 2008 Molecular Vision
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will also contribute to improve their clinical classification,
management, and eventual genetic counseling. Although the
R124C mutation is one of the genetic causes of the disease,
different genetic and environmental factors may govern the
age of onset.
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